Lygos Appoints Bryce Dille as Vice President of Finance

Biotech and cleantech finance veteran to manage company’s financing
and financial operations

BERKELEY, Calif.–(BUSINESS WIRE)–Lygos,
Inc., a full-stack producer of specialty chemicals that deliver
high-value performance without the environmental toxicity, today
announced the appointment of Bryce Dille as Vice President of Finance.
He will lead the company’s finance strategy and oversee the accounting,
corporate development, investor relations, tax, and treasury functions.

Dille brings nearly 20 years of corporate finance, investment banking
and capital markets experience. He has a strong track record in
financing, having secured more than $500 million in both equity and debt
financing before joining Lygos. He previously held senior financial
positions at emerging public and private biotechnology companies,
including Omada Health and TerraVia (formerly Solazyme), which was
acquired by Corbion. Earlier in his career, Dille was a portfolio
manager at Savitr Capital and Vice President and Senior Analyst for
Clean Technology and Renewables at JMP Securities. He earned a Bachelor
of Arts in Chemistry from Carleton College and is a Chartered Financial
Analyst.

“Bryce has extensive experience in both the private and public capital
markets, as well as a keen understanding of biotechnology business and
finances,” said Eric Steen, PhD, CEO of Lygos. “As Lygos grows its
programs and technology platform reach, I’m excited to have Bryce join
us on our quest to replace toxic petrochemicals, reclaim local
manufacturing and revive industrial chemical innovation.”

“Lygos has a solid foundation in place with an experienced management
team, innovative technology platform and multiple strategic partnerships
that can transform the production process for many large-scale
industries,” said Dille. “I’m honored to join this team at this pivotal
time as we look to accelerate our activities to meet the growing demand
around the world for our sustainable, cost-competitive bio-based
solutions.”

Lygos’ proprietary technology platform is based on a high-throughput
combination of computational modeling, unique microbe engineering and
screening, and machine learning. It is used to identify and develop new
bio-routes to chemical functionalities that can expand the performance
window in diverse materials systems. The company applies modern
biotechnology to deliver the benefits of petroleum-based and other
industrial chemical technologies without environmental toxicity at
competitive prices. Lygos’ customers seek sustainable cost-efficient
solutions for applications where industrial chemistry uses expensive,
environmentally degrading options or has none to offer.

About Lygos
Lygos has created a full-stack biological
engineering platform focused on organic acid specialty chemicals and
bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive,
environmentally degrading alternatives from traditional industrial
suppliers, enabling customers to create better, safer products with
value-added performance. For more information, visit www.lygos.com
and follow us @LygosBiotech.

Lygos, the Lygos logo and Bio-Malonic are trademarks of Lygos, Inc.
All other brands may be trademarks of their respective holders.

Contacts

Andrew Noble
(415) 722-2129
[email protected]